[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CL2018000745A1 - Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa. - Google Patents

Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa.

Info

Publication number
CL2018000745A1
CL2018000745A1 CL2018000745A CL2018000745A CL2018000745A1 CL 2018000745 A1 CL2018000745 A1 CL 2018000745A1 CL 2018000745 A CL2018000745 A CL 2018000745A CL 2018000745 A CL2018000745 A CL 2018000745A CL 2018000745 A1 CL2018000745 A1 CL 2018000745A1
Authority
CL
Chile
Prior art keywords
oxo
amino
sulfoazetidin
oxooxazolidin
aminothiazol
Prior art date
Application number
CL2018000745A
Other languages
English (en)
Inventor
Lindvall Mika
Casarez Anthony
Reck Folkert
Lowell Simmons Robert
Aubin Eric
Fisch Andreas
Li Zaixing
Ernst Moser Heinz
Mutz Michael
Ulrich Riebesehl Bernd
Schoenhentz Marc
Sethuraman Vijay
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2018000745A1 publication Critical patent/CL2018000745A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2018000745A 2015-09-23 2018-03-21 Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa. CL2018000745A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562222430P 2015-09-23 2015-09-23

Publications (1)

Publication Number Publication Date
CL2018000745A1 true CL2018000745A1 (es) 2018-06-22

Family

ID=58385723

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2018000745A CL2018000745A1 (es) 2015-09-23 2018-03-21 Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa.
CL2019003324A CL2019003324A1 (es) 2015-09-23 2019-11-20 Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003324A CL2019003324A1 (es) 2015-09-23 2019-11-20 Sales y formas sólidas de un antibiótico de monobactam. (divisional solicitud 201800745)

Country Status (25)

Country Link
US (1) US10919887B2 (es)
EP (1) EP3353175B1 (es)
JP (1) JP6837480B2 (es)
KR (1) KR20180054816A (es)
CN (1) CN108137573B (es)
AU (1) AU2016327264B2 (es)
CA (1) CA2999794C (es)
CL (2) CL2018000745A1 (es)
CY (1) CY1123509T1 (es)
DK (1) DK3353175T3 (es)
EA (2) EA037569B1 (es)
ES (1) ES2817537T3 (es)
HK (1) HK1257271A1 (es)
HR (1) HRP20201423T1 (es)
HU (1) HUE050849T2 (es)
IL (1) IL258254B (es)
LT (1) LT3353175T (es)
MA (1) MA42946B1 (es)
MX (1) MX2018003592A (es)
PH (1) PH12018500653A1 (es)
PT (1) PT3353175T (es)
RS (1) RS60805B1 (es)
RU (1) RU2754180C2 (es)
SI (1) SI3353175T1 (es)
WO (1) WO2017050218A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3661933B1 (en) * 2017-08-02 2022-03-23 Novartis AG Process for preparing 1-(((z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid
US11760866B2 (en) * 2017-08-16 2023-09-19 Lg Chem, Ltd. White pigment comprising ZIF-based powder, polymer resin film and method for changing color of medium using white pigment
US20200360349A1 (en) * 2017-11-10 2020-11-19 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
CN111511737B (zh) * 2018-01-29 2022-10-18 南京明德新药研发有限公司 用于治疗细菌感染的单环β-内酰胺化合物
JP7179185B2 (ja) * 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β-ラクタム化合物の使用
KR20220084398A (ko) * 2019-11-22 2022-06-21 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Technology Co., Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG
CN113754651B (zh) 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
WO2022027439A1 (en) * 2020-08-06 2022-02-10 Ningxia Academy Of Agriculture And Forestry Sciences β-LACTAM COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
US4782147A (en) 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
KR900005112B1 (ko) 1982-05-31 1990-07-19 반유세이야꾸 가부시끼가이샤 2-옥소-1-아제티딘술폰산 유도체의 제조방법
DE3377061D1 (en) 1982-06-03 1988-07-21 Hoffmann La Roche Process for the preparation of 1-sulfo-2-oxoazetidine derivatives
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2−オキソ−1−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
AU2009310959B2 (en) 2008-10-31 2015-05-07 Shionogi & Co., Ltd. Cephalosporin having catechol group
MX2011006541A (es) * 2008-12-19 2011-07-20 Pfizer Monocarbamas.
AU2011336209B2 (en) 2010-11-29 2015-03-19 Pfizer Inc. Monobactams
UY34585A (es) * 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use
BR112016020333B1 (pt) * 2014-03-24 2022-08-09 Novartis Ag Compostos orgânicos de monobactam, seus usos, composições e combinações farmacêuticas

Also Published As

Publication number Publication date
DK3353175T3 (da) 2020-09-14
IL258254A (en) 2018-05-31
EA037569B1 (ru) 2021-04-15
RU2018114480A3 (es) 2020-06-09
HUE050849T2 (hu) 2021-01-28
AU2016327264A1 (en) 2018-05-10
CN108137573A (zh) 2018-06-08
RU2018114480A (ru) 2019-10-23
PT3353175T (pt) 2020-09-10
HRP20201423T1 (hr) 2020-12-11
ES2817537T3 (es) 2021-04-07
CL2019003324A1 (es) 2020-04-17
CA2999794A1 (en) 2017-03-30
BR112018005805A2 (pt) 2018-10-16
CY1123509T1 (el) 2022-03-24
RU2754180C2 (ru) 2021-08-30
US10919887B2 (en) 2021-02-16
CN108137573B (zh) 2021-06-11
EP3353175B1 (en) 2020-08-12
EP3353175A4 (en) 2019-06-26
KR20180054816A (ko) 2018-05-24
HK1257271A1 (zh) 2019-10-18
RS60805B1 (sr) 2020-10-30
LT3353175T (lt) 2020-10-12
EP3353175A1 (en) 2018-08-01
MA42946B1 (fr) 2020-10-28
JP2018528241A (ja) 2018-09-27
EA202092620A1 (ru) 2021-06-30
US20180273522A1 (en) 2018-09-27
JP6837480B2 (ja) 2021-03-03
CA2999794C (en) 2023-08-15
IL258254B (en) 2021-02-28
MX2018003592A (es) 2018-06-18
SI3353175T1 (sl) 2020-11-30
MA42946A (fr) 2018-08-01
WO2017050218A1 (en) 2017-03-30
AU2016327264B2 (en) 2019-06-27
EA201890771A1 (ru) 2018-09-28
PH12018500653A1 (en) 2018-10-01

Similar Documents

Publication Publication Date Title
CL2018000745A1 (es) Sales y formas solidas del acido 1-(((z)-(1-(2-aminotiazol-4-il)-2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidin-3-il)metil)-1-sulfoazetidin-3-il)amino)etilideno)amino)oxi)ciclopropanocarboxilico; metodos de preparacion; formas cristalinas; composicion farmaceutica; uso en el tratamiento de una infeccion bacteriana gram negativa.
WO2016109663A3 (en) Derivatives and methods of treating hepatitis b infections
WO2016131067A3 (en) Pharmaceutical compositions comprising meloxicam
EP3505620A4 (en) 2D ORGANOID FOR INFECTIONS AND GROWTH OF HUMAN DIARRHOEVIRUS AND USE OF THE TWO-DIMENSIONAL ORGANOID
CL2015003298A1 (es) Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
DK3805233T3 (da) (r)- og (s)-enantiomerer af n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinoxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazol-carboxamid som irak4-hæmmere til cancerbehandling
WO2015170322A3 (en) Compositions and methods of using same for increasing resistance of infected mosquitoes
CL2013000399A1 (es) Compuestos derivados de ester de acido boronico; composicion farmaceutica; recipiente esteril; metodo de preparacion; y su uso para el tratamiento o la prevencion de una infeccion bacteriana.
CL2012003723A1 (es) Compuestos derivados de acido 2-quinolinil-acetico; composicion farmaceutica; y uso en el tratamiento del vih y sida.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
CL2011002941A1 (es) Sales de disacarina, acido difumarico, acido di-1-hidroxi-2-naftoico y acido monobenzoico de 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo; composicion farmaceutica; y uso en el tratamiento de asma, epoc, cancer, vih, hepatitis b y c, infecciones bacterianas.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2014000149A1 (es) Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
AR103680A1 (es) Inhibidores selectivos de bace1
WO2009009759A3 (en) Yersinia pestis antigens, vaccine compositions, and related methods
CL2013003229A1 (es) Compuestos inhibidores del virus de la hepatitis c (vhc); composicion farmaceutica que los comprende; y uso en el tratamiento de una infeccion por vhc.
AR085856A1 (es) Formas cristalinas del acido (2s)-2-ter-butoxi-2-(4-(2,3-dihidropirano[4,3,2-de]quinolin-7-il)-2-metilquinolin-3-il)acetico
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
WO2015024010A3 (en) Substituted hydroxamic acid compounds
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
CR20170314A (es) Formulación de relación fija de insulina glargina/lixisenatida
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids